Karrer W
Luzerner Höhenklinik Montana.
Schweiz Rundsch Med Prax. 1990 May 22;79(21):657-60.
By reducing the anti-tuberculous therapy to six to nine months and the fact that tuberculosis occurs in immunocompromised patients raises the question of relapse after treatment. In order to avoid such relapses the drug therapy has to be optimized regarding duration (minimum six months) as well as combination (bactericidal antituberculous drugs) and the patients' compliance has to be monitored carefully. Special monitoring is necessary with immunocompromised patients. The problem of resistance against antituberculous drugs (especially Isoniazid) has to be taken into consideration. The most relapses occur during the first year after termination of therapy.
将抗结核治疗疗程缩短至六至九个月，以及结核病在免疫功能低下患者中发生这一事实，引发了治疗后复发的问题。为避免此类复发，必须在疗程（至少六个月）以及联合用药（杀菌性抗结核药物）方面优化药物治疗，并且必须密切监测患者的依从性。免疫功能低下患者需要进行特殊监测。必须考虑对抗结核药物（尤其是异烟肼）的耐药问题。大多数复发发生在治疗结束后的第一年。
